NCT02328612View on ClinicalTrials.gov

Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Sepsis
Interventions
OTHER

Intravenous infusion of cells

"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."

Trial Locations (1)

Unknown

Academic Medical Center, Amsterdam

All Listed Sponsors
lead

Tigenix S.A.U.

INDUSTRY

NCT02328612 - Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers | Biotech Hunter | Biotech Hunter